HOUSTON, TX / ACCESS Newswire / July 9, 2025 / Mann Eye Institute, a leader in innovative eye care since the 1970s, is proud ...

Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye in children that is based on watching TV ...

An artist who underwent sight-saving surgery has been inspired to pick up the brushes again – to create a portrait of her son ...

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

Outcome Capital, LLC, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ...

Inconsistent fees paid to doctors and facilities show the disadvantage independent clinicians face in the market.

The Tecnis Symfony OptiBlue IOL, a violet light-filtering extended depth of focus lens implant, yielded positive vision ...

This is an overview of systematic reviews to evaluate the visual outcomes of different presbyopia correcting intraocular lens ...

European leader in laser technologies, announces that its subsidiary Lumibird Photonics Sweden AB has secured two major contracts awarded by Saab AB to supply ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

A digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve vision correction over standard therapy in a phase 3 trial, according to its developer ...

Gaining Sight After Years of Blindness Takes Time. Visual areas of the brain need to learn to organize and interpret sensory ...